UnitedHealth’s Optum Rx To Coax Patients To Less Pricey Biosimilars Of Abbvie’s Humira UnitedHealth Group’s OptumRx will put biosimilar versions of Abbvie’s pricey rheumatoid arthritis drug Humira “in the same position as the brand” on the PBM’s formulary in 2023.